US (MA): Strategic partnership to bring cannabis products to Massachusetts

Og DNA Genetics has announced a licensing agreement with Revolutionary Clinics, a producer and distributor of medical and recreational cannabis in Massachusetts.

"The agreement will grant Revolutionary Clinics license to the DNA brand and access to their proprietary library of award-winning genetics for use at Revolutionary Clinics cultivation in Fitchburg, Mass," the team with the company explains. "Along with the approximately 200,000-square-foot facility for indoor cultivation, Revolutionary Clinics also boasts two dispensary locations serving Somerville, Cambridge and the greater Boston area."

Revolutionary Clinics started as a nonprofit, providing heart screens to young patients. After the founder’s daughter died of an opioid overdose, the company pivoted, encouraged by studies demonstrating reduced opioid deaths in areas with friendlier cannabis laws.

"For more than 15 years, genetics developed by DNA have won more than 200 awards in all categories at the most prestigious cannabis events around the world, making DNA the global standard in breeding and growing truly best-in-class strains," they further explain. "These awards include the High Times ‘Top 10 Strain of the Year,’ which was inducted into The High Times seedbank hall of fame in 2009, the High Times 100 list of the most influential people in the industry and the High Times Trailer Blazers Award, for contributions made towards uniting the fields of entrepreneurship, politics and medicine."

“We are excited for the opportunity to partner with DNA Genetics, as they are truly a world-class leader in genetics,” said Ryan Ansin, CEO of Revolutionary Clinics. “With our state-of-the-art cultivation facility and dispensaries, combined with their commitment to quality standards, we will be able to bring the best strains to life in Massachusetts."

For more information:
DNA Genetics
+31 207 787 220     

Publication date:

Receive the daily newsletter in your email for free | Click here

Other news in this sector:

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.

Click here for a guide on disabling your adblocker.